Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1332700 10.3389/fphar.2024.1332700 Pharmacology Policy and Practice Reviews The anatomy of a data transfer agreement for health research Swales et al. 10.3389/fphar.2024.1332700 Swales Lee 1 * Gooden Amy 1 Thaldar Donrich 1 2 1 School of Law, University of KwaZulu-Natal, Durban, South Africa 2 Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School, Cambridge, MA, United States

Edited by: Lijun Shang, London Metropolitan University, United Kingdom

Reviewed by: Davit Chokoshvili, Luxembourg National Data Service, Luxembourg

Rania Mohamed Hassan Baleela, University of Khartoum, Sudan

*Correspondence: Lee Swales, SwalesL@ukzn.ac.za
27 08 2024 2024 15 1332700 03 11 2023 25 07 2024 Copyright © 2024 Swales, Gooden and Thaldar. 2024 Swales, Gooden and Thaldar

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

In a data-driven era, the exchange and safeguarding of personal information has become paramount. Data transfer agreements (DTAs) serve to guard privacy, defining the rules for sharing and protecting sensitive data. Yet, the complexities surrounding issues such as data privacy, intellectual property, and dispute resolution within these agreements pose challenges that demand careful consideration. Through a scoping review of twenty-four publicly available, English language DTAs relevant to health research, this article undertakes a comprehensive analysis, examining common clauses, their vital components, and charting a course for responsible data sharing through the provision of insights and practical guidance for drafting DTAs. The article underscores the need for attention to detail and an understanding of data protection legislation in order to ensure that DTAs align with the law and maximize legal certainty.

data data transfer agreement research scoping review South Africa U01MH127690 National Institutes of Health10.13039/100000002 section-at-acceptance ELSI in Science and Genetics

香京julia种子在线播放

    1. <form id=HxFbUHhlv><nobr id=HxFbUHhlv></nobr></form>
      <address id=HxFbUHhlv><nobr id=HxFbUHhlv><nobr id=HxFbUHhlv></nobr></nobr></address>

      1 Introduction

      In a scientific and research context, the transfer of personal information has become routine. One of the key tools used in data protection compliance, and as part of a holistic data management strategy, is a data transfer agreement (DTA). Lawfully managing and strategically sharing data will arguably become more important than it is at present, where already, for at least the past decade, society has recognized that data has value, and the mantra: “data is the new oil” has become an oft-repeated line (Parkins, 2017; Swales, 2022). For example, the proliferation of artificial intelligence technologies, such as OpenAI’s ChatGPT, that rely on data to produce meaningful output, has further fast-tracked discussions around data transfer, ownership, and management. Additionally, techniques and strategies relating to sharing data are evolving rapidly and should always recognize the value in some scientific and academic output. Even where data that does not contain personal information is shared—and, as such, data protection legislation will not apply—it is imperative that this is done intentionally and, in all circumstances, with an eye on the legal consequences (and with consideration for its ownership and value). In most scenarios where data is shared with others, it should be done via a DTA or similar instrument.

      What is a DTA? It is a written agreement that facilitates the lawful transfer of data between parties. Typically, an agreement of this type will seek to comply with applicable legislation. Additionally, a DTA will regulate other important legal issues such as ownership of data, intellectual property, the terms of the agreement and how it will terminate, liability, dispute resolution, and whether any consideration is payable (Swales et al., 2023a).

      This article presents an empirical study of twenty-four DTAs relevant to health research, which were examined to identify the specific clauses contained therein to tease out key trends and differences. This scoping review facilitates the main part of this article—an anatomy, or dissection, of a DTA, where we examine key features of this type of agreement, and make recommendations on critical inclusions together with insight on why these clauses are necessary. This novel scoping review will animate parts of our discussion and assist in providing the guidance set out herein. Accordingly, the purpose of this contribution is to provide academics, researchers, scientists, ethicists, research managers, and all interested stakeholders with guidance on steps to take prior to executing a DTA, and insight into what to include in their own DTAs. Each case will no doubt have nuances and turn on its own facts. To be clear: There is no “one size fits all” template that can be uniformly applied without thought. However, there are many elements of a DTA that will be similar, and the holistic purpose of this discussion is to identify typical features of such an agreement, review best practice, and make recommendations for stakeholders going forward.

      2 Scoping review 2.1 Methodology and results

      Although there is no one standard DTA template and the contents of each will depend on certain factors, there are several clauses common to many DTAs. In order to ascertain and understand the key clauses used in DTAs that are contained in the health research space, we conducted a scoping review of publicly available and English-language DTAs. The search terms used are recorded in Supplementary Material 1. The inclusion criterion was that a DTA had to relate to data generally (and hence be inclusive of health research), or specific to health research. To ensure a broad, yet manageable spread of samples, our aim was to collect at least twenty samples, and to ensure that there are at least two samples from the Global South. When we reached twenty-four samples (B3 Africa, 2018; Bristol Myers Squibb, 2017; Clinical Study Data Request Consortium, 2015; Department of Health Western Australia, 2021; Dkfz German Cancer Research Center, 2020; FDP, 2017; Fred Hutch, 2020; GREGoR Consortium, 2022; Growing Up in New Zealand, 2014; Health Data Coalition, 2017; Human Cell Atlas, 2019; Indian Society of Critical Care Medicine, 2024; Infectious Diseases Data Observatory, 2021; Information Commissioner’s Office, 2022; Johns Hopkins University, 2022; Kawartha Lakes OHT, 2020; KEMRI Wellcome Trust Research Programme, 2019; National Center for Advancing Translational Sciences, 2021; National Institute for Medical Research, 2020; National Health Service England, 2018; ONDC, 2024; Swiss Personalised Health Network, 2021; University of Newcastle, 2024; Utrecht University, 2024) containing two samples from Africa (B3 Africa, 2018; KEMRI Wellcome Trust Research Programme, 2019) and one from India (Indian Society of Critical Care Medicine, 2024), we decided that we had reached saturation point. Each DTA was examined to identify the specific clauses contained therein. The most frequently occurring clauses across the twenty-four DTAs were identified. These clauses were tabulated and categorized to facilitate a comprehensive comparison (see Supplementary Material 2). To gain insights into the prevalence and consistency of these clauses, their content was compared across all DTAs. Through this comparison, the common features shared by the clauses were identified—and encompassed language, structure, and substantive content of the provisions. The common clauses that we found were:

      • Introduction (preamble/recitals), definitions, and parties.

      • Purpose.

      • Term and termination.

      • Obligations on parties.

      • Reporting and auditing.

      • Intellectual property (and licensing).

      • Data ownership.

      • Publication and attribution.

      • Confidentiality.

      • Limitation of liability.

      • General provisions (or miscellaneous).

      • Governing law.

      • Dispute resolution.

      2.2 Limitations

      Our study does have limitations. First, the sample size of twenty-four DTAs, while broad and representative of five continents, was intentionally kept to a size that we perceived as manageable. Second, our scoping review was confined to agreements available in the English language and freely accessible online. As such, the results may not fully capture the global landscape of DTAs. A further caveat is that terminology and definitions that are used in DTAs may vary across jurisdictions, and that the substantive provisions found in DTAs may cater for specific institutional needs or reflect domestic (national) legal requirements. Nevertheless, we suggest that the results of our scoping exercise are informative and useful. In the next section, we discuss the results in more detail.

      3 Discussion: key features of a data transfer agreement 3.1 Introduction, definitions, and parties

      Most commercial agreements begin with an introduction, also known as a preamble, or recitals (also referred to as “whereas” clauses). Like any good story or piece of writing, the introduction provides exactly that: An introduction to what is about to come. As Murray (2018) points out, this clause identifies the “who, what, when, and why” in the agreement. As noted by an English court in Toomey Motors v Chevrolet (2017), the fact that this clause is introductory in nature, does not mean its provisions are not binding, and these clauses may contain “operative provisions.”

      However, it is a matter of style and personal preference in deciding which clause comes first, and the order that follows. One might also see a definitions clause coming first, and that clause being followed by the introductory clause. The definitions clause is usually accompanied by an interpretation clause. This is a technical legal clause that provides a list of definitions and legal interpretative clauses. Usually, words used in the agreement with a capital letter will be defined terms and will be included in the definitions list—a definition is included in the agreement to assist with flow, and to aid the reader. For example, if a word or term has a long and/or complicated meaning, it is usually included in the definitions list (for example, “Intellectual Property” or “Processing Purpose”).

      Typically, near the start of the agreement, there is a clause that fully describes the parties to the agreement. This, as is the case with many parts of a contract, can be achieved in a multitude of ways: A clause on its own, or as part of the introduction, included in the definitions, or even on the cover page.

      Given the importance of introductions and explanations, most of the DTAs that we analyzed included some form of introduction, definitions, and information about the parties—although these did vary depending on the DTA. Some provided an introduction or background (Bristol Myers Squibb, 2017; Clinical Study Data Request Consortium, 2015; Department of Health Western Australia, 2021; Fred Hutch, 2020; Growing Up in New Zealand, 2014; Health Data Coalition, 2017; Human Cell Atlas, 2019; Infectious Diseases Data Observatory, 2021; Information Commissioner’s Office, 2022; National Center for Advancing Translational Sciences, 2021; ONDC, 2024; University of Newcastle, 2024), while others contained a recital (Dkfz German Cancer Research Center, 2020; Fred Hutch, 2020; Kawartha Lakes OHT, 2020; National Institute for Medical Research, 2020; Swiss Personalised Health Network, 2021; Indian Society of Critical Care Medicine, 2024). Some of the DTAs included a definitions section (Bristol Myers Squibb, 2017; Clinical Study Data Request Consortium, 2015; Department of Health Western Australia, 2021; Dkfz German Cancer Research Center, 2020; Fred Hutch, 2020; GREGoR Consortium, 2022; Growing Up in New Zealand, 2014; Health Data Coalition, 2017; Human Cell Atlas, 2019; Indian Society of Critical Care Medicine, 2024; Infectious Diseases Data Observatory, 2021; Kawartha Lakes OHT, 2020; KEMRI Wellcome Trust Research Programme, 2019; National Institute for Medical Research, 2020; Swiss Personalised Health Network, 2021; Utrecht University, 2024.), although in some it appeared as an appendix or glossary (GREGoR Consortium, 2022; Information Commissioner’s Office, 2022; National Health Service England, 2018). All twenty-four DTAs provided information about the parties or a blank space in which information could be added.

      3.2 Purpose

      A purpose clause sets out the primary intention of the parties and articulates the nature of the agreement. This clause provides additional context, and sets out rights, responsibilities, and restrictions. In the context of a DTA, it is important to record the data transfer, the reason for the transfer, and note any important restrictions and obligations on the parties.

      Ten of the DTAs that we examined contained a specific purpose clause (Department of Health Western Australia, 2021; Dkfz German Cancer Research Center, 2020; Human Cell Atlas, 2019; Indian Society of Critical Care Medicine, 2024; Information Commissioner’s Office, 2022; Kawartha Lakes OHT, 2020; National Health Service England, 2018; ONDC, 2024; Swiss Personalised Health Network, 2021; University of Newcastle, 2024). Although some DTAs may not have a specific “purpose” clause, information relevant to the purpose was nevertheless included in other clauses (B3 Africa, 2018; Bristol Myers Squibb, 2017; Clinical Study Data Request Consortium, 2015; FDP, 2017; Fred Hutch, 2020; GREGoR Consortium, 2022; Health Data Coalition, 2017; Infectious Diseases Data Observatory, 2021; Johns Hopkins University, 2022; KEMRI Wellcome Trust Research Programme, 2019; National Center for Advancing Translational Sciences, 2021; National Institute for Medical Research, 2020; Utrecht University, 2024).

      There is significant variance in how narrow or broad, general or detailed purpose statements are formulated, which may be a reflection of the legal tradition in the relevant jurisdiction. This is demonstrated by the following example:

      Improvements in information sharing, translate into many tangible benefits. Repeat diagnostic tests can be avoided. Medical errors are reduced and outcomes improved with quicker access to complete information. Time is saved by physicians, staff and patients. With less manual processing of information and fewer phone calls for results, patients can be cared for quicker.

      Ultimately patients will be more engaged in their care by leveraging the technology where providers and patients can securely access necessary PHI.

      Participants may include hospitals, healthcare organizations and healthcare providers involved in the circle of care that or who have direct involvement in the delivery of patient care, which requires the communication and sharing of patient information.

      This data sharing agreement is entered into by the Participants to enable more effective and efficient patient information sharing that then will translate into better patient care (Kawartha Lakes OHT, 2020).

      By contrast, the University of Newcastle (2024) DTA contains a checklist of the various purposes for which the data is to be used:

      The Data is to be used only for the study of eating behaviours. Please indicate from the options below how you intend to use the Data:

      • Training and evaluation of new machine learning models for the detection of eating behaviours

      • Benchmarking existing machine learning models for the detection of eating behaviours

      • Creating and/or analyzing metrics of eating behaviors (e.g., eating pace and duration)

      • Other. Please specify (University of Newcastle, 2024):

      An insightful drafting note is included in the National Health Service England (2018) template agreement in the purpose clause to assist those that use the template (the advice should be heeded in developing any purpose clause). An excerpt of it is below:

      Document the detail to explain the purpose and objectives of the information sharing … ensure that all parties affected by the information sharing are clear about why the information may be used… National Health Service England (2018)

      We suggest that all the purposes of the sharing should be listed. It should be made clear which organization is processing the data and for which purpose. It is important to specify this in sufficient detail and exactness, as DTAs typically limit the processing of the data by the recipient to the defined purpose. In other words, should the data recipient process the data for any purpose other than the defined purpose, it would be in breach of contract.

      3.3 Term and termination

      An important feature of any agreement is its term, and the manner of its termination. One must also be aware of the agreement’s effective date (the date the agreement is binding from). With a DTA, usually there is a fixed term, with the ability for either party to give notice to the other to terminate (also known as cancellation for convenience—or no-fault termination—where one party does not need to give a reason for termination). Linked to this clause, one will usually also see a termination for fault or cause (a breach clause), and a clause which sets out how termination for convenience should be achieved. Some of the DTAs that we analyzed dealt with term and termination under one clause (Clinical Study Data Request Consortium, 2015; Bristol Myers Squibb, 2017; Fred Hutch, 2020; Infectious Diseases Data Observatory, 2021; Indian Society of Critical Care Medicine, 2024), while others either dealt with term and termination separately, or combined them with another clause (B3 Africa, 2018; Department of Health Western Australia, 2021; Dkfz German Cancer Research Center, 2020; FDP, 2017; GREGoR Consortium, 2022; Growing Up in New Zealand, 2014; Health Data Coalition, 2017; Human Cell Atlas, 2019; Information Commissioner’s Office, 2022; Johns Hopkins University, 2022; Kawartha Lakes OHT, 2020; KEMRI Wellcome Trust Research Programme, 2019; National Center for Advancing Translational Sciences, 2021; National Institute for Medical Research, 2020; National Health Service England, 2018; Swiss Personalised Health Network, 2021; University of Newcastle, 2024; Utrecht University, 2024).

      Above all, parties should know: (1) when the agreement is effective from; (2) how long it lasts for; and (3) how they can terminate the agreement, and under what circumstances. Below are two examples of this type of clause:

      Term and Termination. 22.1 This Agreement shall be effective as of the Effective Date and, unless cancelled or terminated earlier in accordance with the terms hereof, shall continue in effect until 30 September 2002 (the “Initial Term”). Thereafter, this Agreement shall continue in force and effect unless and until cancelled or terminated as provided in this Agreement (Law Insider, 2024).

      Termination for Convenience. Either party may terminate this Agreement without cause and at any time upon giving 30 days’ prior written notice to the other party (each, a termination for “Convenience”). Such termination will be effective on the date stated in the notice (NetDocuments, 2024).

      The first example displays a fixed term agreement clause where the agreement comes to an end on a specific date. Parties would also be able to terminate for cause on the basis of a clause found elsewhere in that agreement. The second example shows a termination for convenience clause where either party can terminate the agreement on notice without any fault and without having to give a reason. This type of clause provides maximum flexibility. Typically, where research institutions are involved, for the protection of both parties, one would want to see a termination for convenience clause so that a party is not forced to stay in a relationship that does not suit it. However, there may be economic or other factors that require the contract to exist for a long period, and for no termination for convenience to exist. Each case will turn on its own facts and this is a point parties must consider carefully.

      Below are two examples of term and termination clauses found in the DTAs that we examined:

      7.1. This Agreement shall come into force on the Effective Date and will remain in effect for a period of one (01) year from the Effective Date or on the expiration of a thirty (30) days’ written notice by either party.

      7.2. This Agreement will terminate immediately upon any breach of the provisions of this Agreement by the Recipient or by any of the Registered Users.

      7.3. In the event that this Agreement is terminated in accordance with this Clause 7.1 or 7.2, the Recipient shall return or destroy all Data at the direction of the Provider (Indian Society of Critical Care Medicine, 2024).

      And:

      This Agreement will expire on the completion of the Research and completion of the publications included in the Publication Plan but in no event later than three (3) years from the Effective Date. BMS may terminate this Agreement for Institution’s material breach of its terms, where the breach is not cured within thirty (30) days following receipt of written notice of same. Upon termination or expiration of this Agreement the rights and obligations of the Parties which have accrued hereunder shall survive in accordance with their terms, and Institution’s right to use BMS Confidential Information shall immediately cease. The terms of Section 3 (Term and Termination), 4 (Institution Representations, Warranties and Covenants), 5 (Confidentiality), 6 (Publication), 7 (Inventions), 8 (Miscellaneous) shall survive the expiration or termination of this Agreement (Bristol Myers Squibb, 2017).

      3.4 Obligations on parties

      The clause (or clauses) that set out the main obligations of the parties can be drafted in many ways, and different headings can be used. Twenty-one of the DTAs that we examined contained a clause (or information) detailing the obligations or duties of the parties to the agreement (B3 Africa, 2018; Clinical Study Data Request Consortium, 2015; Department of Health Western Australia, 2021; Dkfz German Cancer Research Center, 2020; FDP, 2017; Fred Hutch, 2020; GREGoR Consortium, 2022; Growing Up in New Zealand, 2014; Health Data Coalition, 2017; Human Cell Atlas, 2019; Infectious Diseases Data Observatory, 2021; Information Commissioner’s Office, 2022; Johns Hopkins University, 2022; Kawartha Lakes OHT, 2020; KEMRI Wellcome Trust Research Programme, 2019; National Center for Advancing Translational Sciences, 2021; National Institute for Medical Research, 2020; National Health Service England, 2018; Swiss Personalised Health Network, 2021; University of Newcastle, 2024; Utrecht University, 2024).

      Below is an excerpt of a DTA clause which lists the obligations (we have only reproduced part of the clause because of its length) of the parties:

      It is hereby agreed that the following conditions to the Agreement shall be binding on the RECIPIENT:

      (a) The RECIPIENT agrees to use, store or dispose of the DATA in compliance with all applicable laws including those relating to research involving the use of human and animal subjects.

      (b) The DATA shall remain the property of the PROVIDER and PROVIDER hereby consents to the DATA being made available as a service to the research community.

      (c) The RECIPIENT shall use the DATA for teaching or academic research purposes only.

      It is hereby agreed that the following conditions to the Agreement shall be binding on the PROVIDER:

      (a) The PROVIDER agrees to transfer, store or dispose of the DATA in compliance with all applicable laws

      (b) The PROVIDER shall transfer immediately the DATA upon receipt of one of the two copies duly signed by the RECIPIENT (National Institute for Medical Research, 2020).

      This clause creates contractual obligations (or duties) on both parties. Usually, one would expect to find the key responsibilities of the parties in this clause. In the context of a DTA, primarily, one should ensure the clause places obligations on the parties to comply with the conditions of lawful processing set out in South Africa’s Protection of Personal Information Act 4 of 2013 (POPIA), 2013 (or equivalent international legislation). As can be seen in the example above, both the provider and recipient have a duty to ensure compliance with “all applicable laws”—one could craft this to specifically refer to data protection legislation, such as POPIA.

      Typically, one would also see obligations on the parties in relation to dealing with data after the relationship ends (in other words, to return or delete it), and in terms of how to use the data (such as for teaching or academic research purposes only). If there are specific requirements or nuances to a project, this is the clause that will list those requirements. We suggest that parties give careful thought to what the project entails—simply put, what is it each party needs to do in order to achieve a successful outcome, and then to ensure these obligations are listed in this clause.

      Holistically, we suggest that a DTA can be a useful tool to facilitate compliance with data protection legislation. In this context, parties may consider including provisions that relate to the following:

      • The ground of justification for the transfer;

      • The manner in which the data was collected, how it will be processed, transferred, stored, and disposed of;

      • Data subject access rights;

      • Appropriate technical and organizational measures are taken, and that adequate safeguards are in place;

      • Measures in place in relation to cross border data flows;

      • Conditions and restrictions in place in relation to further processing of data beyond.

      Parties should also ensure that the details and mechanics of the data being transferred are included in the agreement. As all of the agreements that we examined are DTAs, they all mention the transfer of data in some form. However, not all DTAs described the mechanics of such transfers (Growing Up in New Zealand, 2014; Clinical Study Data Request Consortium, 2015; Bristol Myers Squibb, 2017; Health Data Coalition, 2017; National Health Service England, 2018; KEMRI Wellcome Trust Research Programme, 2019; Dkfz German Cancer Research Center, 2020; Kawartha Lakes OHT, 2020; Department of Health Western Australia, 2021; Indian Society of Critical Care Medicine, 2024; University of Newcastle, 2024; Utrecht University, 2024). Twelve DTAs provided more detailed guidance relating to transfers of data (B3 Africa, 2018; FDP, 2017; Fred Hutch, 2020; GREGoR Consortium, 2022; Human Cell Atlas, 2019; Infectious Diseases Data Observatory, 2021; Information Commissioner’s Office, 2022; Johns Hopkins University, 2022; National Center for Advancing Translational Sciences, 2021; National Institute for Medical Research, 2020; ONDC, 2024; Swiss Personalised Health Network, 2021). For practical reasons, this could be an annexure. Only six DTAs provided for the transfer of data in an annexure (FDP, 2017; Human Cell Atlas, 2019; Fred Hutch, 2020; National Institute for Medical Research, 2020; Swiss Personalised Health Network, 2021; Johns Hopkins University, 2022).

      3.5 Reporting and auditing

      An example of an a-typical clause in a DTA relates to auditing and reporting. Only two of the DTAs in our scoping review contained an audit clause (Growing Up in New Zealand, 2014; Kawartha Lakes OHT, 2020), which appear as follows:

      The Privacy Officer of each Participant shall audit access to PHI for which the Participant is the Custodian, including without limitation access by its Authorized Users (Kawartha Lakes OHT, 2020).

      And:

      A representative of UniServices will be permitted access by the Institution, at all reasonable times, to the results and analyses obtained from the use of the Data Set together with any records and documents relating thereto for the purpose of verifying compliance with the conditions of this Agreement. The Institution will provide UniServices with any information which UniServices reasonably requests in relation to the Institution’s compliance with this Agreement (Growing Up in New Zealand, 2014).

      The primary purpose of a clause such as this is to allow the provider to ensure that the recipient is taking adequate steps to comply with its obligations. Despite the importance of this clause, very few of the DTAs that we analyzed contained specific clauses relevant to reporting and auditing (Growing Up in New Zealand, 2014; Kawartha Lakes OHT, 2020; Infectious Diseases Data Observatory, 2021). None of the DTAs examined contained a specific reporting clause, and in eight of the DTAs reporting is instead mentioned either generally throughout the agreement or under another clause (Health Data Coalition, 2017; National Health Service England, 2018; Kawartha Lakes OHT, 2020; Infectious Diseases Data Observatory, 2021; Swiss Personalised Health Network, 2021; GREGoR Consortium, 2022; Indian Society of Critical Care Medicine, 2024; University of Newcastle, 2024).

      One will also see clauses that require one party to report to the other in relation to, for example, processing activities with the data, and safeguards in place—and in some cases this type of obligation may be found in the main obligations clause discussed above in 3.4. Parties should consider what best suits their needs in the context of the data involved. However, we do suggest parties should have some ability to assess whether the other party is complying with the agreement.

      3.6 Intellectual property and licensing

      A specific intellectual property (IP) clause was present in twelve of the DTAs that we examined (B3 Africa, 2018; Clinical Study Data Request Consortium, 2015; Department of Health Western Australia, 2021; Dkfz German Cancer Research Center, 2020; Fred Hutch, 2020; Growing Up in New Zealand, 2014; Human Cell Atlas, 2019; Indian Society of Critical Care Medicine, 2024; Infectious Diseases Data Observatory, 2021; Swiss Personalised Health Network, 2021; University of Newcastle, 2024; Utrecht University, 2024), with another four dealing with IP under other clauses (Bristol Myers Squibb, 2017; KEMRI Wellcome Trust Research Programme, 2019; Kawartha Lakes OHT, 2020; National Institute for Medical Research, 2020).

      IP clauses are like Janus, with one face looking back and one face looking forward. It looks back in the sense that it recognizes pre-existing IP rights, often termed as “background” IP. It also looks forward, and provides for rights in any new IP that is created by the Recipient using the Project Data. Typically, the Recipient will own the IP that it creates using the Project Data, but this can be negotiated. For example, the Recipient can grant a perpetual nontransferable use-license to the Provider in the IP that it creates, or the parties can be joint owners of the IP. Here is an example of a simple IP clause:

      Except for the rights explicitly granted hereunder, nothing contained in this Agreement shall be construed as conveying any rights under any patents or other intellectual property which either Party may have or may hereafter obtain (Human Cell Atlas, 2019).

      Licensing is often dealt with under the IP clause. Ten of the DTAs from our scoping review include licensing within IP (Clinical Study Data Request Consortium, 2015; Bristol Myers Squibb, 2017; Human Cell Atlas, 2019; Dkfz German Cancer Research Center, 2020; Fred Hutch, 2020; Department of Health Western Australia, 2021; Infectious Diseases Data Observatory, 2021; Swiss Personalised Health Network, 2021; Indian Society of Critical Care Medicine, 2024; University of Newcastle, 2024). Examples of licensing provisions (within an IP clause) is as follows:

      Provider grants to Recipient the non-exclusive, worldwide, perpetual, sub-licensable, royalty-free, fully paid up license to use all Data for Recipient’s non-commercial, research and educational purposes (Indian Society of Critical Care Medicine, 2024).

      And:

      Subject to any pre-existing rights, obligations, options to license, or licenses granted by the Provider and/or Recipient to a third party, the Recipient and Provider retain or are granted a non-exclusive royalty-free license to use an Invention developed under the Purpose for their own research, educational, patient care purposes but not for Commercial Use unless otherwise outlined in the Implementing Letter (Fred Hutch, 2020).

      Licensing is mentioned in relation to ownership as well as commercialization, as can be seen below:

      The University grants the Recipient Organisation a non-exclusive, non-transferable, fee-free licence to use the Data for the Purpose only.

      If the Recipient Organisation wishes to commercialise or have commercialised any Results or Data IP, or otherwise deal in the Data or Derivatives for any commercial purpose, it must first enter into an appropriate licence agreement with the University (University of Newcastle, 2024).

      Next, we consider data ownership. It is important to note that although both data ownership and IP pertain to incorporeal objects, data ownership and IP are distinct legal concepts and are governed by different legal rules.

      3.7 Data ownership

      The Project Data would presumably consist of one or more computer files—i.e., digital objects. Each of these digital objects has an independent existence in the digital world, has value and usefulness, and can be controlled by humans. As such, in legal systems that have a basis in Roman Law, the Project Data should be susceptible of being owned (Thaldar et al., 2022). Yet, data ownership remains controversial in the West. By contrast, China is leading the way with the adoption of a policy on the commercialization of data, released in 2022 (Xiong et al., 2023). This policy provides for various property rights modules in data. If the data contains personal information, a privacy module applies to the data in addition to the property rights modules. With China officially endorsing data as legal property, we suggest that it would be unwise for the rest of the world to remain in data ownership purgatory.

      It is essential to address and dispel the primary objection to data ownership, especially concerning personal data. This argument is structured as follows:

      • Premise 1: In certain situations, the ownership rights of a data generator (like a university) might conflict with the privacy rights of data subjects.

      • Premise 2: Political and legal policies underscore the importance of data privacy rights, as evidenced by the growing body of global legislation on the matter.

      • Conclusion: Therefore, data ownership is viewed as politically and legally untenable.

      While the premises are true, the conclusion does not necessarily hold. Thaldar et al. (2022) argue that ownership is always encumbered in some way, depending on the nature of the object and the circumstances. In the context of personal data, ownership is encumbered by privacy rights, allowing for a reconciliation between data ownership and data privacy. This perspective aligns with China’s approach that provides that if data is personal data, the property rights in such data are superseded by the privacy rights of the data subjects. In a recent article, Thaldar (2024) turns the anti-data-ownership argument on its head by showing that research institutions can only properly fulfil their statutory duties to protect the personal data in their care if they actively claim ownership in such data. Thaldar (2024) uses an example of a person who has lawful access to the data at a research institution, such as a research collaborator or a student, who makes a copy of the file containing the relevant data on her own memory stick and deletes the original file from the research institution’s system. Subsequently, the person declares herself the owner of the data contained in the file on the memory stick. If the research institution shunned data ownership, it has none of the well-established civil and criminal remedies of an owner available. It will have to rely on its contractual relationship with the person who took the data, which places it in a significantly weaker position. As Thaldar (2024) concludes, data ownership is a precondition for being an effective data custodian.

      In agreements like DTAs, we propose that while ensuring the protection of individuals’ data privacy rights through contractual obligations is crucial, as discussed above under Section 3.4, it is equally important to explicitly articulate ownership rights. This dual focus can harmonize the protection of privacy with the recognition of data as a valuable and ownable asset.

      Let’s now consider the results of the scoping review. Sixteen of the DTAs that are part of our scoping review mention “ownership.” However, on closer inspection, only six of these DTAs unambiguously provide for data ownership—i.e., where the object of ownership is data per se, as distinct from rights in data, such as IP rights in data (B3 Africa, 2018; Human Cell Atlas, 2019; Indian Society of Critical Care Medicine, 2024; National Institute for Medical Research, 2020; Swiss Personalised Health Network, 2021; University of Newcastle, 2024). This is an important distinction. Claiming only IP rights in data and remaining silent about the data itself, means that ownership of the data itself—which is independent of any IP rights in the data—remains unresolved. Yet, this is the case in the majority of the DTAs that we reviewed. Two DTAs even conflate the objects of ownership (Dkfz German Cancer Research Center, 2020; Utrecht University, 2024). For example, one DTA provides:

      The RECIPIENT recognizes that nothing in this Agreement shall operate to transfer to the RECIPIENT or its RECIPIENT SCIENTISTs any INTELLECTUAL PROPERTY rights in or relating to the DATA, i.e., ownership of DATA remains unchanged (Dkfz German Cancer Research Center, 2020).

      This kind of conceptual confusion should be avoided. A clear data ownership provision, such as the following simple provision should be included in any DTA:

      As this is an ISCCM initiated project, the entire ownership of the data will be with the ISCCM (Indian Society of Critical Care Medicine, 2024).

      It is important that data ownership exists independently and distinctly from ownership of rights in the data, such as IP rights. As such, it makes sense to deal with these two kinds of objects of ownership in under separate headings. However, it can also be successfully combined in a single clause, provided that the concepts are not conflated, as illustrated by the following provision:

      The Receiving Institute will own all Research Data, results, inventions, copyright in datasets, sui generis database rights, and all associated rights, which arise which arise under the Research Project described in Appendix A (Human Cell Atlas, 2019).

      An argument that is sometimes heard in academic circles is that because there is legal uncertainty about data ownership in a given jurisdiction, referring to data ownership should best be avoided as a component of a DTA. This argument is mistaken. If there is still a dearth of caselaw on data ownership in a given jurisdiction, resulting in the issue not yet being settled law, this fact is good reason to explicitly provide for data ownership in a DTA—in this way, the parties are bound to the agreed position. For example, if a recipient agreed that the provider is the owner of the project data (qua well-defined digital object), the recipient could be estopped from later asserting in court that the provider is not the owner. Accordingly, including an explicit data ownership provision in a DTA creates legal certainty—even in an environment of general uncertainty.

      3.8 Publication and attribution

      Typically, in data transfers involving universities or research institutions, one can expect to see a clause regulating the publication of results and/or academic publications. Only one DTA in our scoping review contained a specific attribution clause (Human Cell Atlas, 2019), but thirteen DTAs included publication clauses (B3 Africa, 2018; Bristol Myers Squibb, 2017; Clinical Study Data Request Consortium, 2015; Department of Health Western Australia, 2021; Dkfz German Cancer Research Center, 2020; Fred Hutch, 2020; Health Data Coalition, 2017; Human Cell Atlas, 2019; Indian Society of Critical Care Medicine, 2024; Infectious Diseases Data Observatory, 2021; Swiss Personalised Health Network, 2021; University of Newcastle, 2024; Utrecht University, 2024). In eight of the DTAs, publication was mentioned under another clause (Growing Up in New Zealand, 2014; FDP, 2017; KEMRI Wellcome Trust Research Programme, 2019; National Institute for Medical Research, 2020; National Center for Advancing Translational Sciences, 2021; GREGoR Consortium, 2022; Johns Hopkins University, 2022; ONDC, 2024).

      As a starting point, we recommend that no results are released unless the other party consents. However, it is not unusual to expect that the party who provided the data would want the right to stipulate whether or not the results are published, and to retain the right to derive benefit from academic publications.

      Further, given obligations imposed by data protection legislation, it is prudent to insert a provision regulating how results are made public. An example may appear as follows:

      As SPHN projects are funded with public money, the Parties strive to make the resulting scientific publications publicly accessible and available through Open access as far as possible according to publishers rights (Swiss Personalised Health Network, 2021).

      And:

      The Receiving Institute must endeavour to publish results in an open access academic journal or database (Human Cell Atlas, 2019).

      One would also expect to see something here, including an obligation to make acknowledgments. Fifteen DTAs required acknowledgements to be made in publications arising from the provider’s data (B3 Africa, 2018; Bristol Myers Squibb, 2017; Department of Health Western Australia, 2021; Dkfz German Cancer Research Center, 2020; Fred Hutch, 2020; Growing Up in New Zealand, 2014; Health Data Coalition, 2017; Human Cell Atlas, 2019; Indian Society of Critical Care Medicine, 2024; Infectious Diseases Data Observatory, 2021; KEMRI Wellcome Trust Research Programme, 2019; National Center for Advancing Translational Sciences, 2021; National Institute for Medical Research, 2020; Swiss Personalised Health Network, 2021; University of Newcastle, 2024). An example of such a provision reads as follows:

      Publications: Unless directed otherwise, HDC must be acknowledged in any publication or presentation using HDC data, and the following disclaimer must appear on any materials developed for public distribution with data used under this DSA: “The views expressed herein do not necessarily represent the views of HDC (Health Data Coalition, 2017).”

      And:

      Recipient will acknowledge the Provider as the source of the Data in any publication reporting on its use, unless requested otherwise by the Provider (Indian Society of Critical Care Medicine, 2024).

      And:

      The Institution will ensure that all outputs that are intended for publication, including (but not necessarily limited to) reports, journal papers, working papers, conference and other public presentations, and other documents, contains an acknowledgement that the Data Set has been sourced from The University of Auckland, Growing Up in New Zealand: Longitudinal Study of New Zealand Children and Families, together with an appropriate acknowledgement of the funders of the study, all of which must be approved by the Data Access Committee in writing prior to the publication (Growing Up in New Zealand, 2014).

      3.9 Confidentiality

      A confidentiality provision is a standard clause in any commercial agreement, and a DTA is no exception. As with any other clause, there are many ways to draft this—typically, the clause stipulates that each party will keep all information (which will be broadly defined) confidential, and will not, without the prior written consent of the other party, disclose to any person any of the confidential information. This prohibition on disclosure of confidential information will usually not preclude any party from making any disclosure to its professional advisors (provided that the advisors ensure the information remains confidential). Further, it will preclude a party from making any disclosure which it is required to make by law (such as in the course of an investigation around a data breach).

      The importance of confidentiality can be seen in the fact that thirteen of the DTAs in our scoping review contained a dedicated clause dealing with confidentiality (B3 Africa, 2018; Bristol Myers Squibb, 2017; Clinical Study Data Request Consortium, 2015; Department of Health Western Australia, 2021; Dkfz German Cancer Research Center, 2020; Fred Hutch, 2020; Health Data Coalition, 2017; Human Cell Atlas, 2019; Indian Society of Critical Care Medicine, 2024; Kawartha Lakes OHT, 2020; Swiss Personalised Health Network, 2021; University of Newcastle, 2024; Utrecht University, 2024). An additional five DTAs, although not including a dedicated confidentiality clause, mentioned confidentiality—in some form or another—throughout the DTA (National Health Service England, 2018; KEMRI Wellcome Trust Research Programme, 2019; Infectious Diseases Data Observatory, 2021; National Center for Advancing Translational Sciences, 2021; GREGoR Consortium, 2022). An example of a confidentiality clause is as follows:

      Either PARTY shall treat the CONFIDENTIAL INFORMATION confidential for the duration of this Agreement, including any extension thereof, and thereafter for a period of five (5) years following termination or expiry of this Agreement. Excluded from this obligation of confidentiality shall be any CONFIDENTIAL INFORMATION of which one PARTY can reasonably demonstrate that it (a) was previously known to them, or (b) is, and/or becomes, publicly available during said five (5) year period through no fault of a PARTY, or (c) is independently and lawfully developed by one PARTY. This obligation of confidentiality shall not apply to any disclosure required by law, provided that the RECIPIENT shall notify the PROVIDER of any disclosure required by law in sufficient time so that the PROVIDER may contest such requirement, if the PROVIDER so chooses. Subject to mandatory law, upon the expiration or termination of this Agreement for whatever reason, or at the earlier request of a PARTY, the other PARTY shall, at its own costs, return or destroy all originals and copies of CONFIDENTIAL INFORMATION, or, in case of CONFIDENTIAL INFORMATION stored in electronic, magnetic or digital media, shall erase or render unreadable all materials furnished (including without limitation, working papers containing any CONFIDENTIAL INFORMATION or extracts therefrom) which contain CONFIDENTIAL INFORMATION (Swiss Personalised Health Network, 2021).

      And—note that Human Cell Atlas (2019) defines “Research Materials” to include, inter alia, “Research Data collected for the Research Project”:

      8.1. The Information may include confidential information of the Providing Institute. Accordingly, if and to the extent that any such Information is marked as “confidential,” the Receiving Institute shall during the Term of this Agreement and for a period of [insert period] following its termination, treat such Information as confidential and only disclose it under like obligations of confidentiality and Restrictions on Use as those contained herein. The Receiving Institute shall be deemed to have fulfilled its obligation if it [insert local criteria applicable to confidentiality standards/requirements].

      8.2. The above-mentioned obligations of confidentiality shall not apply to Information which:

      8.2.1. [If contributing derived Research Data to the HCA: Is identified as Research Data to be contributed to the HCA by the Providing Institute/Receiving Institute, as listed in Appendix A]; or

      8.2.2. Can be shown to have been known to the Receiving Institute at the time of its acquisition from Providing Institute; or

      8.2.3. Is acquired from a third party, not in breach of any confidentiality obligation to the Providing Institute; or

      8.2.4. Is independently devised or arrived at by, on behalf of, or for the Receiving Institute without access to the Information; or

      8.2.5. Enters the public domain otherwise than by breach of the undertakings set out in this Agreement.

      8.3. In some cases, the Research Materials may also incorporate confidential Information pertaining to research participants or donors having provided the Research Materials. The Research Materials provided to the Receiving Institute have been [enter information related to de-identification processes applied to the data, e.g., coded, double-coded, anonymized, anonymous (provide description of de-identification measures)]. If the Receiving Institute inadvertently receives Information that identifies individual research participants or donors, the Receiving Institute will take all reasonable and appropriate steps to protect the privacy and confidentiality of such Information. This may require immediate destruction of the Research Materials on request of the Providing Institute. The Receiving Institute agrees to make no intentional attempt to re-identify research participants or donors, through linkage of data or otherwise. The Receiving Institute will immediately report any identification of research participants or donors to the Providing Institute (Human Cell Atlas, 2019).

      3.10 Limitation of liability

      Another of the “boilerplate” clauses (those clauses which you see in almost every commercial agreement, irrespective of what the agreement regulates), is a clause limiting the liability of the parties—sometimes, this may be coupled with indemnities. In larger, more complicated commercial deals these two clauses will be separated, but for purposes of a data transfer, it may well be that one can combine them. Nine of the DTAs in our scoping review contained a liability clause (which is often combined with warranties) (B3 Africa, 2018; Department of Health Western Australia, 2021; Growing Up in New Zealand, 2014; Human Cell Atlas, 2019; Indian Society of Critical Care Medicine, 2024; Information Commissioner’s Office, 2022; Kawartha Lakes OHT, 2020; Swiss Personalised Health Network, 2021; Utrecht University, 2024). In eleven DTAs, liability is mentioned under another clause, such as limitations and exclusions (Infectious Diseases Data Observatory, 2021), data sharing (Clinical Study Data Request Consortium, 2015), disclaimer (GREGoR Consortium, 2022), terms and conditions (FDP, 2017; National Center for Advancing Translational Sciences, 2021; Johns Hopkins University, 2022), indemnification (Fred Hutch, 2020), warranty and indemnities (University of Newcastle, 2024), legal statement (Dkfz German Cancer Research Center, 2020), remedies and no waiver (National Health Service England, 2018), and obligations of provider and recipient (National Institute for Medical Research, 2020).

      In terms of the various limitation of liability provisions, for the most part, where the clause exists, it attempts to protect the provider of the data, and ensure that it will not be liable for damages relating from the use or transfer of the data (B3 Africa, 2018; Dkfz German Cancer Research Center, 2020; FDP, 2017; Human Cell Atlas, 2019; Indian Society of Critical Care Medicine, 2024; Infectious Diseases Data Observatory, 2021; Johns Hopkins University, 2022; National Institute for Medical Research, 2020; Utrecht University, 2024).

      An example of this clause is as follows:

      Providing Institute will not be liable for damages related to the provision of Research Materials to the Receiving Institute. This includes but is not limited to damages in relation to inaccuracies, lack of comprehensiveness, or use of the Research Materials, or any delays or break in supply by the Providing Institute (Human Cell Atlas, 2019).

      Interestingly, two of the DTAs required that parties take out, and maintain, liability insurance for the duration of the agreement (Kawartha Lakes OHT, 2020; Department of Health Western Australia, 2021)—with one DTA specifying the value of the insurance (Kawartha Lakes OHT, 2020).

      We suggest that the limitations, as far as possible, should be reciprocal, and that both parties indemnify each other from unlawful conduct. Importantly, both parties should identify a figure that represents the entire amount any party could claim from another. The context will determine the appropriate figure, and this will be informed by the level of risk, insurance cost, and benefit derived from the project.

      Parties should also ensure that neither party will be liable for loss of profits or consequential damages arising out of the project.

      Further examples of liability clauses are as follows:

      11.1 Providing Institute makes no warranty, either express or implied, of the fitness for purpose of the Research Material. However, to the best of Providing Institute’s knowledge, the use of the Research Materials within the Purpose of Use shall not infringe on the proprietary rights of any third party.

      11.2 Providing Institute will not be liable for damages related to the provision of Research Materials to the Receiving Institute. This includes but is not limited to damages in relation to inaccuracies, lack of comprehensiveness, or use of the Research Materials, or any delays or break in supply by the Providing Institute. The Receiving Institute acknowledges that the Providing Institute makes no guarantee that the Research Materials are free of contamination from viruses, latent viral genomes, or other infectious agents. The Receiving Institute agrees to treat the Research Materials as if they were not free from contamination, to ensure that appropriate biosafety training is provided to research personnel, and to implement appropriate biohazard containment measures.

      11.3 The Receiving Institute agrees that, except as may explicitly be provided for in this Agreement, the Providing Institute has no control over the use that is made of the Research Materials or the Information by the Receiving Institute in accordance with the terms of this Agreement. Consequently, the Receiving Institute agrees that Providing Institute shall not be liable for such use.

      11.4 The Receiving Institute will not be liable for damages incurred by the Providing Institute in providing the Research Materials to the Receiving Institute. This includes but is not limited to damages incurred through the Providing Institute’s breach of contract or statute, its breach of institutional policy, research ethics requirements, as well as any tortious or extracontractual liability incurred (Human Cell Atlas, 2019).

      And:

      Except to the extent prohibited by law, the Recipient assumes all liability for damages which may arise from its use, storage, disclosure, or disposal of the Data. The Provider will not be liable to the Recipient for any loss, claim, or demand made by the Recipient, or made against the Recipient by any other party, due to or arising from the use of the Data by the Recipient, except to the extent permitted by law when caused by the gross negligence or willful misconduct of the Provider (FDP, 2017).

      And:

      6.1 Nothing in this Agreement excludes or limits the liability of either Party:

      6.1.1 for death or personal injury caused by that Party’s negligence; or

      6.1.2 for fraud or fraudulent misrepresentation; or

      6.1.3 to the extent that such liability cannot be limited or excluded by law.

      6.2 Subject to Clause 6.1, in no event will the University of Oxford or the Data Contributor(s) be liable for any use of the Dataset by the Recipient, whether in contract, tort (including negligence or breach of statutory duty) or otherwise howsoever arising (Infectious Diseases Data Observatory, 2021).

      3.11 General provisions (miscellaneous)

      Fourteen of the twenty-four DTAs that we examined contained a heading for general provisions, or sometimes called “Miscellaneous” (B3 Africa, 2018; Bristol Myers Squibb, 2017; Department of Health Western Australia, 2021; GREGoR Consortium, 2022; Growing Up in New Zealand, 2014; Health Data Coalition, 2017; Human Cell Atlas, 2019; Indian Society of Critical Care Medicine, 2024; Infectious Diseases Data Observatory, 2021; Information Commissioner’s Office, 2022; National Health Service England, 2018; Swiss Personalised Health Network, 2021; University of Newcastle, 2024; Utrecht University 2024). The general clauses serve as a backbone to the overall contract, addressing various fundamental legal, operational, and administrative aspects that govern the relationship between the parties involved. These clauses are pivotal for ensuring clarity, legality, and fair practice in data transfers. The components (or sub-clauses) commonly found in these clauses are as follows:

      • Waiver: This provision clarifies that the failure or delay in enforcing any part of the agreement does not constitute a waiver of rights.

      • Assignment and Novation: This provision dictates the conditions under which parties can transfer their rights and obligations under the DTA to another party.

      • Relationship of the Parties: It clarifies that the DTA does not create a partnership, joint venture, or agency relationship between the parties.

      • Amendment: This specifies that changes to the DTA must be made in writing and signed by all parties.

      • Severability: If any part of the DTA is found to be invalid or unenforceable, this provision allows for that part to be removed without affecting the remainder of the DTA.

      • Entire Agreement: This provision states that the DTA constitutes the full and complete agreement between the parties, superseding all prior discussions and agreements.

      Less common, but very useful components of general clauses are:

      • Survival Clause: This provision specifies which provisions of the agreement will continue to be effective after the termination or expiry of the agreement. For example, the Department of Health Western Australia (2021) DTA specifies that certain clauses will survive the termination or expiry of the agreement.

      • Counterparts: Some DTAs, like those of National Health Service England (2018), allow the agreement to be executed in counterparts, meaning separate copies can be signed and assembled to form the complete agreement.

      • Contact Points and Notices: This provision specifies how formal communications related to the DTA should be made, often requiring written notices, as seen in the University of Newcastle (2024) DTA.

      • Electronic Signatures and Form: With the advancement of technology, some DTAs, like the Swiss Personalised Health Network (2021), acknowledge electronic signatures and communications.

      Two provisions that are sometimes found as sub-clauses under the general clause, but also frequently as self-standing clauses, are governing law and dispute resolution. We discuss these two provisions next.

      3.12 Governing law

      The inclusion of a governing law provision is a fundamental aspect of a DTA, as it establishes which country’s law will govern the interpretation of the DTA. Typically, a governing law provision will also provide which court within the relevant country has jurisdiction to adjudicate disputes that arise from the DTA. In our analysis, it was observed that almost all the DTAs reviewed incorporate a governing law provision. Only six DTAs (FDP, 2017; KEMRI Wellcome Trust Research Programme, 2019; National Center for Advancing Translational Sciences, 2021; GREGoR Consortium, 2022; Johns Hopkins University, 2022; ONDC, 2024) eschew this essential element.

      The DTAs that contain a governing law provision typically specify the country whose law will govern the DTA. However, in two cases, the Human Cell Atlas (2019) and B3 Africa (2018), the choice of jurisdiction is left open for the parties to decide.

      Interestingly, among the eighteen DTAs that do include a governing law provision, ten delineate it as an independent clause (Clinical Study Data Request Consortium, 2015; Dkfz German Cancer Research Center, 2020; Fred Hutch, 2020; Human Cell Atlas, 2019; Indian Society of Critical Care Medicine, 2024; Infectious Diseases Data Obervatory, 2021; Information Commissioner’s Office, 2022; Kawartha Lakes OHT, 2020; National Institute for Medical Research, 2020; Swiss Personalised Health Network, 2021), seven integrate it within the general or miscellaneous provisions (B3 Africa, 2018; Bristol Myers Squibb, 2017; Department of Health Western Australia, 2021; Growing Up in New Zealand, 2014; National Health Service England, 2018; University of Newcastle, 2024; Utrecht University 2024), and one defines the governing law under its definitions/interpretations section (Health Data Coalition, 2017). This differentiation in presentation underscores the varied approaches to structuring DTAs.

      An example of a governing law clause is found in the Utrecht University (2024) DTA. It reads as follows:

      This agreement will be governed by the laws of Netherlands and disputes concerning its execution will be put before the competent district court of Utrecht (Utrecht University, 2024).

      We suggest that this concise example is worth emulation. The absence of such a governing law clause means that resolving disputes could become complicated, potentially necessitating judicial intervention to ascertain applicable laws. Such situations could lead to unforeseen legal entanglements and protracted disputes, which could counteract the purpose of the DTA.

      3.13 Dispute resolution

      Most DTAs in our scoping review dealt with dispute resolution in some form. Of the twenty-four DTAs that we examined, four contained a dedicated dispute resolution clause (Growing Up in New Zealand, 2014; National Health Service England, 2018; Human Cell Atlas, 2019; Kawartha Lakes OHT, 2020). Twelve of the DTAs dealt with (or simply mentioned) dispute resolution under another clause (B3 Africa, 2018; Bristol Myers Squibb, 2017; Clinical Study Data Request Consortium, 2015; Department of Health Western Australia, 2021; Dkfz German Cancer Research Center, 2020; Fred Hutch, 2020; Health Data Coalition, 2017; Indian Society of Critical Care Medicine, 2024; Information Commissioner’s Office, 2022; National Institute for Medical Research, 2020; Swiss Personalised Health Network, 2021; Utrecht University, 2024)—most commonly the governing law clause or the general provisions clause. Those DTAs that dealt with disputes under the governing law or general provisions clauses referred to the jurisdiction and the laws that will apply (Bristol Myers Squibb, 2017; Clinical Study Data Request Consortium, 2015; Dkfz German Cancer Research Center, 2020; Indian Society of Critical Care Medicine, 2024; Information Commissioner’s Office, 2022; Swiss Personalised Health Network, 2021; Utrecht University, 2024). Others mentioned alternative dispute resolution mechanisms, such as arbitration, negotiation, and mediation (B3 Africa, 2018; Department of Health Western Australia, 2021; Fred Hutch, 2020; Growing Up in New Zealand, 2014; Health Data Coalition, 2017; Human Cell Atlas, 2019; Indian Society of Critical Care Medicine, 2024; Information Commissioner’s Office, 2022; Kawartha Lakes OHT, 2020; National Institute for Medical Research, 2020; National Health Service England, 2018).

      Holistically, it is important to ensure that the clause provides clarity on how a dispute will be managed—and, in our view, a tiered approach is best in this type of relationship. What do we mean by a tiered approach? The parties should be obliged to try and meet first to find a solution to the dispute by negotiation (usually senior representatives from both sides), failing that, a formal mediation, and then an arbitration using well known rules. However, parties should include a provision that acknowledges that either party may be able to approach a court of law on an urgent basis. In some cases, parties may need urgent or interim relief pending the outcome of the negotiations, mediation, or arbitration, and it is wise to ensure that a party is not prevented from seeking such urgent, interim relief.

      We also suggest including a provision to stipulate that the mediation or arbitration will be held via video conferencing, unless the parties agree otherwise—this will likely assist from a cost saving perspective, and should also expediate matters. Following the COVID-19 pandemic, video conferencing, such as Zoom and Microsoft Teams, is commonplace.

      Ultimately, a dispute resolution clause should provide the parties with an efficient, pragmatic, and cost-effective manner to resolve any dispute. An example of a dispute resolution clause is as follows:

      16.1 All disputes arising out of or in connection with this Agreement shall be settled under the Rules of Arbitration of the International Chamber of Commerce by one or more arbitrators appointed in accordance with the said Rules.

      16.2 The Parties agree, pursuant to Article 30 (2) (b) of the Rules of Arbitration of the International Chamber of Commerce, that the Expedited Procedure Rules shall apply, provided the amount in dispute does not exceed US$ [specify amount] at the time of the communication referred to in Article 1 (3) of the Expedited Procedure Rules.

      16.3 The Parties agree that arbitration shall be conducted in [CITY] at [PLACE].

      16.4 Legal proceedings brought by a Party while this Agreement is in force, and legal proceedings brought by a Party arising out of or in connection with this Agreement may only be brought in the courts of [JURISDICTION] at [JUDICIAL DISTRICT]. This clause shall only have effect if, for any reason, a dispute cannot be brought to arbitration pursuant to the preceding clauses (Human Cell Atlas, 2019).

      4 Conclusion

      In a rapidly evolving data-driven landscape, DTAs stand as foundational instruments governing the exchange of data across various sectors, from scientific research to commercial partnerships. This comprehensive analysis sheds light on the critical clauses that underpin DTAs, highlighting their importance in facilitating secure, efficient, and legally compliant data-sharing relationships and providing guidance on the drafting of such clauses. Drafting DTAs requires attention to detail, a nuanced understanding of data protection regulations and, often, legal expertise. DTAs are pivotal, not only for safeguarding data, but also for fostering collaboration, innovation, and responsible data sharing. With the guidance and insights provided in this article, stakeholders can navigate the complexities of data transfers, maximize legal certainty, and adhere to evolving data protection laws.

      We should mention that the findings of the scoping review formed the basis for an open-source DTA template that was developed for the South African research community (Swales et al., 2023a; Swales et al., 2023b).

      Author contributions

      LS: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Writing–original draft, Writing–review and editing. AG: Methodology, Writing–review and editing. DT: Formal Analysis, Investigation, Methodology, Writing–review and editing.

      Funding

      The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Work on this article was supported by the U.S. National Institute of Mental Health and the U.S. National Institutes of Health (award number U01MH127690) under the Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) program. The content of this article is solely our responsibility and does not necessarily represent the official views of the U.S. National Institute of Mental Health or the U.S. National Institutes of Health.

      The authors wish to thank their research assistants, Roasia Hazarilall, Kiara Munsamy, Jodie de Klerk, and Naseeba Sadak. OpenAI’s ChatGPT-4 was used to improve language and readability.

      Conflict of interest

      The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

      Publisher’s note

      All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

      Supplementary material

      The Supplementary Material for this article can be found online at: /articles/10.3389/fphar.2024.1332700/full#supplementary-material

      References B3 Africa (2018). Data transfer agreement. Available at: https://www.researchgate.net/publication/357269852_DATA-TRANSFER-AGREEMENT (Accessed September 12, 2022). Bristol Myers Squibb (2017). Data sharing agreement. Available at: https://www.bms.com/assets/bms/us/english-documents/independent-research/sample-data-sharing-agreement.docx (Accessed September 12, 2022). Clinical Study Data Request Consortium (2015). Data sharing agreement. Available at: https://www.clinicalstudydatarequest.com/Documents/DATA-SHARING-AGREEMENT.pdf (Accessed September 12, 2022). Department of Health Western Australia (2021). Material and data transfer agreement. Available at: https://rgs.health.wa.gov.au/Documents/Material%20and%20Data%20Transfer%20Agreement%20v1%2012%20Nov%202021.docx (Accessed September 12, 2022). Dkfz German Cancer Research Center (2020). Data transfer agreement of human data for research purposes. Available at: https://www.dkfz.de/en/CanEpi/EGA/Data-Transfer-Agreement-of-Human-Data-for-Research-Purposes-Jan.-2020.pdf (Accessed October 3, 2023). FDP (2017). Data transfer and use agreement. Available at: https://www.uthscsa.edu/sites/default/files/Services/forms/duatemplate.pdf (Accessed September 12, 2022). Fred Hutch (2020). Multi-party data and material transfer agreement. Available at: https://research.fredhutch.org/content/dam/stripe/specimen-acquisition-network/COL210703_Umbrella%20Data%20and%20Material%20Transfer%20Agreement_FH_FINAL%20no%20org%20list.pdf (Accessed September 12, 2022). GREGoR Consortium (2022). Data sharing agreement. Available at: https://gregorconsortium.org/sites/default/files/policies/GREGoR%20Consortium%20Data%20Sharing%20Agreement%20V1.0_Fillable.pdf (Accessed October 5, 2023). Growing Up in New Zealand (2014). Data access agreement. Available at: https://cdn.auckland.ac.nz/assets/growingup/access-to-data/External%20DA%20Agreement_1003a_V2.pdf (Accessed September 12, 2022). Health Data Coalition. (2017). Data sharing agreement. Human Cell Atlas (2019). Template: material/data transfer agreement (MDTA). Available at: https://docs.google.com/document/d/1MpUXC7ayY7RAYeZrEMbEdoYn2l-rIBDR/edit (Accessed October 3, 2023). Indian Society of Critical Care Medicine (2024). Data transfer agreement. Available at: https://isccm.org/isccm_v1/pdf/data_transfer_agreement.pdf (Accessed March 5, 2024). Infectious Diseases Data Observatory (2021). COVID-19 data platform: data transfer agreement. Available at: https://www.iddo.org/sites/default/files/publication/2021-03/COVID-19%20Data%20Transfer%20Agreement%2016MAR21.pdf (Accessed September 12, 2022). Information Commissioner’s Office (2022). International data transfer agreement. Available at: https://ico.org.uk/media/for-organisations/documents/4019538/international-data-transfer-agreement.pdf (Accessed October 3, 2023). Johns Hopkins University (2022). Data transfer and use agreement. Available at: https://jhura.jhu.edu/wp-content/uploads/2022/03/DUATemplate_Updated.pdf (Accessed October 5, 2023). Kawartha Lakes OHT (2020). Data sharing agreement. Available at: https://pub-kawarthalakes.escribemeetings.com/filestream.ashx?DocumentId=37434 (Accessed September 12, 2022). KEMRI Wellcome Trust Research Programme (2019). Application form for access to KWTRP data. Available at: https://kemri-wellcome.org/zp-content/uploads/2021/02/KWTRP_Dataverse_Data_Request_Form_2019.docx (Accessed October 3, 2023). Law Insider (2024). Term and termination sample clauses. Available at: https://www.lawinsider.com/clause/term-and-termination (Accessed October 2, 2023). Murray J. (2018). What is a contract: preamble/recitals - let’s begin at the beginning. AMM. Available at: https://www.ammlaw.com/blog/what-is-a-contract-preamble/-recitals-lets-begin-at-the-beginning.html (Accessed October 2, 2023). National Center for Advancing Translational Sciences (2021). Data transfer agreement. Available at: https://ncats.nih.gov/files/NCATS_Data_Transfer_Agreement_508.pdf (Accessed September 12, 2022). National Health Service (NHS) England (2018). Template data sharing agreement. Available at: https://www.england.nhs.uk/wp-content/uploads/2019/04/appendix-4-sample-data-sharing-agreement.docx (Accessed October 3, 2023). National Institute for Medical Research (2020). Data transfer agreement for researchers/organizations. Available at: http://reims.nimr.or.tz:8010/guides/DTA.pdf (Accessed September 12, 2022). NetDocuments (2024). Termination for convenience clause samples. Available at: https://afterpattern.com/clauses/termination-for-convenience#:∼:text=TPI%20COMPOSITES%2C%20INC)-,Termination%20for%20Convenience.,date%20stated%20in%20the%20notice (Accessed October 2, 2023). ONDC (2024). Data sharing agreement. Available at: https://www.datacommissioner.gov.au/sites/default/files/2022-07/ONDC_Legislation_Agnostic_DSA_Template.doc (Accessed March 5, 2024). Parkins D. (2017). The world’s most valuable resource is no longer oil, but data. Econ. Available at: https://www.economist.com/leaders/2017/05/06/the-worlds-most-valuable-resource-is-no-longer-oil-but-data (Accessed October 2, 2023). Protection of Personal Information Act 4 of 2013, 2013 (POPIA) [South Africa]. Swales L. (2022). The Protection of Personal Information Act 4 of 2013 in the context of health research: enabler of privacy rights or roadblock? PER/PELJ 25, 132. 10.17159/1727-3781/2022/v25i0a11180 Swales L. Botes M. Donnelly D. Thaldar D. (2023a). Towards a data transfer agreement for the South African research community: the empowerment approach. S. Afr. J. Bioeth. Law. 16 (1), 1318. 10.7196/SAJBL.2023.v16i1.827 Swales L. Ogendi P. Botes M. Townsend B. Donnelly D. L. Abdulrauf L. (2023b). A data transfer agreement template for South Africa. 10.5281/zenodo.7537396 Swiss Personalised Health Network (2021). Data transfer and use agreement. Available at: https://sphn.ch/wp-content/uploads/2021/11/2018DEV21_DTUA_SPHN_SwissPKcdw_V3.0.pdf (Accessed October 3, 2023). Thaldar D. (2024). The wisdom of claiming ownership of human genomic data: a cautionary tale for research institutions. Dev. World Bioeth., 18. 10.1111/dewb.12443 Thaldar D. W. Townsend B. A. Donnelly D. L. Botes M. Gooden A. van Harmelen J. (2022). The multidimensional legal nature of personal genomic sequence data: a South African perspective. Front. Genet. 13, 997595997611. 10.3389/fgene.2022.997595 Toomey Motors v Chevrolet (2017) EWHC 276 (comm) [United Kingdom]. University of Newcastle (2024). Data transfer agreement. Available at: https://www.newcastle.edu.au/__data/assets/pdf_file/0010/631954/Data_Transfer_Agreement_OREBA1.pdf (Accessed March 5, 2024). Utrecht University (2024). Data transfer agreement. Available at: https://www.uu.nl/sites/default/files/data_transfer_agreement_youth_template.pdf (Accessed March 5, 2024). Xiong B. Ge J. Chen L. (2023). Unpacking data: China’s “bundle of rights” approach to the commercialization of data. Int. Data Priv. Law 13, 93106. 10.1093/idpl/ipad003
      ‘Oh, my dear Thomas, you haven’t heard the terrible news then?’ she said. ‘I thought you would be sure to have seen it placarded somewhere. Alice went straight to her room, and I haven’t seen her since, though I repeatedly knocked at the door, which she has locked on the inside, and I’m sure it’s most unnatural of her not to let her own mother comfort her. It all happened in a moment: I have always said those great motor-cars shouldn’t be allowed to career about the streets, especially when they are all paved with cobbles as they are at Easton Haven, which are{331} so slippery when it’s wet. He slipped, and it went over him in a moment.’ My thanks were few and awkward, for there still hung to the missive a basting thread, and it was as warm as a nestling bird. I bent low--everybody was emotional in those days--kissed the fragrant thing, thrust it into my bosom, and blushed worse than Camille. "What, the Corner House victim? Is that really a fact?" "My dear child, I don't look upon it in that light at all. The child gave our picturesque friend a certain distinction--'My husband is dead, and this is my only child,' and all that sort of thing. It pays in society." leave them on the steps of a foundling asylum in order to insure [See larger version] Interoffice guff says you're planning definite moves on your own, J. O., and against some opposition. Is the Colonel so poor or so grasping—or what? Albert could not speak, for he felt as if his brains and teeth were rattling about inside his head. The rest of[Pg 188] the family hunched together by the door, the boys gaping idiotically, the girls in tears. "Now you're married." The host was called in, and unlocked a drawer in which they were deposited. The galleyman, with visible reluctance, arrayed himself in the garments, and he was observed to shudder more than once during the investiture of the dead man's apparel. HoME香京julia种子在线播放 ENTER NUMBET 0016jgchain.com.cn
      www.gamebf.com.cn
      jqrzg.com.cn
      www.hdelec.net.cn
      www.happyfc500.com.cn
      www.kqsyxb.com.cn
      www.qeis.com.cn
      qzjkkj.org.cn
      www.rockderma.com.cn
      pncgzx.com.cn
      处女被大鸡巴操 强奸乱伦小说图片 俄罗斯美女爱爱图 调教强奸学生 亚洲女的穴 夜来香图片大全 美女性强奸电影 手机版色中阁 男性人体艺术素描图 16p成人 欧美性爱360 电影区 亚洲电影 欧美电影 经典三级 偷拍自拍 动漫电影 乱伦电影 变态另类 全部电 类似狠狠鲁的网站 黑吊操白逼图片 韩国黄片种子下载 操逼逼逼逼逼 人妻 小说 p 偷拍10幼女自慰 极品淫水很多 黄色做i爱 日本女人人体电影快播看 大福国小 我爱肏屄美女 mmcrwcom 欧美多人性交图片 肥臀乱伦老头舔阴帝 d09a4343000019c5 西欧人体艺术b xxoo激情短片 未成年人的 插泰国人夭图片 第770弾み1 24p 日本美女性 交动态 eee色播 yantasythunder 操无毛少女屄 亚洲图片你懂的女人 鸡巴插姨娘 特级黄 色大片播 左耳影音先锋 冢本友希全集 日本人体艺术绿色 我爱被舔逼 内射 幼 美阴图 喷水妹子高潮迭起 和后妈 操逼 美女吞鸡巴 鸭个自慰 中国女裸名单 操逼肥臀出水换妻 色站裸体义术 中国行上的漏毛美女叫什么 亚洲妹性交图 欧美美女人裸体人艺照 成人色妹妹直播 WWW_JXCT_COM r日本女人性淫乱 大胆人艺体艺图片 女同接吻av 碰碰哥免费自拍打炮 艳舞写真duppid1 88电影街拍视频 日本自拍做爱qvod 实拍美女性爱组图 少女高清av 浙江真实乱伦迅雷 台湾luanlunxiaoshuo 洛克王国宠物排行榜 皇瑟电影yy频道大全 红孩儿连连看 阴毛摄影 大胆美女写真人体艺术摄影 和风骚三个媳妇在家做爱 性爱办公室高清 18p2p木耳 大波撸影音 大鸡巴插嫩穴小说 一剧不超两个黑人 阿姨诱惑我快播 幼香阁千叶县小学生 少女妇女被狗强奸 曰人体妹妹 十二岁性感幼女 超级乱伦qvod 97爱蜜桃ccc336 日本淫妇阴液 av海量资源999 凤凰影视成仁 辰溪四中艳照门照片 先锋模特裸体展示影片 成人片免费看 自拍百度云 肥白老妇女 女爱人体图片 妈妈一女穴 星野美夏 日本少女dachidu 妹子私处人体图片 yinmindahuitang 舔无毛逼影片快播 田莹疑的裸体照片 三级电影影音先锋02222 妻子被外国老头操 观月雏乃泥鳅 韩国成人偷拍自拍图片 强奸5一9岁幼女小说 汤姆影院av图片 妹妹人艺体图 美女大驱 和女友做爱图片自拍p 绫川まどか在线先锋 那么嫩的逼很少见了 小女孩做爱 处女好逼连连看图图 性感美女在家做爱 近距离抽插骚逼逼 黑屌肏金毛屄 日韩av美少女 看喝尿尿小姐日逼色色色网图片 欧美肛交新视频 美女吃逼逼 av30线上免费 伊人在线三级经典 新视觉影院t6090影院 最新淫色电影网址 天龙影院远古手机版 搞老太影院 插进美女的大屁股里 私人影院加盟费用 www258dd 求一部电影里面有一个二猛哥 深肛交 日本萌妹子人体艺术写真图片 插入屄眼 美女的木奶 中文字幕黄色网址影视先锋 九号女神裸 和骚人妻偷情 和潘晓婷做爱 国模大尺度蜜桃 欧美大逼50p 西西人体成人 李宗瑞继母做爱原图物处理 nianhuawang 男鸡巴的视屏 � 97免费色伦电影 好色网成人 大姨子先锋 淫荡巨乳美女教师妈妈 性nuexiaoshuo WWW36YYYCOM 长春继续给力进屋就操小女儿套干破内射对白淫荡 农夫激情社区 日韩无码bt 欧美美女手掰嫩穴图片 日本援交偷拍自拍 入侵者日本在线播放 亚洲白虎偷拍自拍 常州高见泽日屄 寂寞少妇自卫视频 人体露逼图片 多毛外国老太 变态乱轮手机在线 淫荡妈妈和儿子操逼 伦理片大奶少女 看片神器最新登入地址sqvheqi345com账号群 麻美学姐无头 圣诞老人射小妞和强奸小妞动话片 亚洲AV女老师 先锋影音欧美成人资源 33344iucoom zV天堂电影网 宾馆美女打炮视频 色五月丁香五月magnet 嫂子淫乱小说 张歆艺的老公 吃奶男人视频在线播放 欧美色图男女乱伦 avtt2014ccvom 性插色欲香影院 青青草撸死你青青草 99热久久第一时间 激情套图卡通动漫 幼女裸聊做爱口交 日本女人被强奸乱伦 草榴社区快播 2kkk正在播放兽骑 啊不要人家小穴都湿了 www猎奇影视 A片www245vvcomwwwchnrwhmhzcn 搜索宜春院av wwwsee78co 逼奶鸡巴插 好吊日AV在线视频19gancom 熟女伦乱图片小说 日本免费av无码片在线开苞 鲁大妈撸到爆 裸聊官网 德国熟女xxx 新不夜城论坛首页手机 女虐男网址 男女做爱视频华为网盘 激情午夜天亚洲色图 内裤哥mangent 吉沢明歩制服丝袜WWWHHH710COM 屌逼在线试看 人体艺体阿娇艳照 推荐一个可以免费看片的网站如果被QQ拦截请复制链接在其它浏览器打开xxxyyy5comintr2a2cb551573a2b2e 欧美360精品粉红鲍鱼 教师调教第一页 聚美屋精品图 中韩淫乱群交 俄罗斯撸撸片 把鸡巴插进小姨子的阴道 干干AV成人网 aolasoohpnbcn www84ytom 高清大量潮喷www27dyycom 宝贝开心成人 freefronvideos人母 嫩穴成人网gggg29com 逼着舅妈给我口交肛交彩漫画 欧美色色aV88wwwgangguanscom 老太太操逼自拍视频 777亚洲手机在线播放 有没有夫妻3p小说 色列漫画淫女 午间色站导航 欧美成人处女色大图 童颜巨乳亚洲综合 桃色性欲草 色眯眯射逼 无码中文字幕塞外青楼这是一个 狂日美女老师人妻 爱碰网官网 亚洲图片雅蠛蝶 快播35怎么搜片 2000XXXX电影 新谷露性家庭影院 深深候dvd播放 幼齿用英语怎么说 不雅伦理无需播放器 国外淫荡图片 国外网站幼幼嫩网址 成年人就去色色视频快播 我鲁日日鲁老老老我爱 caoshaonvbi 人体艺术avav 性感性色导航 韩国黄色哥来嫖网站 成人网站美逼 淫荡熟妇自拍 欧美色惰图片 北京空姐透明照 狼堡免费av视频 www776eom 亚洲无码av欧美天堂网男人天堂 欧美激情爆操 a片kk266co 色尼姑成人极速在线视频 国语家庭系列 蒋雯雯 越南伦理 色CC伦理影院手机版 99jbbcom 大鸡巴舅妈 国产偷拍自拍淫荡对话视频 少妇春梦射精 开心激动网 自拍偷牌成人 色桃隐 撸狗网性交视频 淫荡的三位老师 伦理电影wwwqiuxia6commqiuxia6com 怡春院分站 丝袜超短裙露脸迅雷下载 色制服电影院 97超碰好吊色男人 yy6080理论在线宅男日韩福利大全 大嫂丝袜 500人群交手机在线 5sav 偷拍熟女吧 口述我和妹妹的欲望 50p电脑版 wwwavtttcon 3p3com 伦理无码片在线看 欧美成人电影图片岛国性爱伦理电影 先锋影音AV成人欧美 我爱好色 淫电影网 WWW19MMCOM 玛丽罗斯3d同人动画h在线看 动漫女孩裸体 超级丝袜美腿乱伦 1919gogo欣赏 大色逼淫色 www就是撸 激情文学网好骚 A级黄片免费 xedd5com 国内的b是黑的 快播美国成年人片黄 av高跟丝袜视频 上原保奈美巨乳女教师在线观看 校园春色都市激情fefegancom 偷窥自拍XXOO 搜索看马操美女 人本女优视频 日日吧淫淫 人妻巨乳影院 美国女子性爱学校 大肥屁股重口味 啪啪啪啊啊啊不要 操碰 japanfreevideoshome国产 亚州淫荡老熟女人体 伦奸毛片免费在线看 天天影视se 樱桃做爱视频 亚卅av在线视频 x奸小说下载 亚洲色图图片在线 217av天堂网 东方在线撸撸-百度 幼幼丝袜集 灰姑娘的姐姐 青青草在线视频观看对华 86papa路con 亚洲1AV 综合图片2区亚洲 美国美女大逼电影 010插插av成人网站 www色comwww821kxwcom 播乐子成人网免费视频在线观看 大炮撸在线影院 ,www4KkKcom 野花鲁最近30部 wwwCC213wapwww2233ww2download 三客优最新地址 母亲让儿子爽的无码视频 全国黄色片子 欧美色图美国十次 超碰在线直播 性感妖娆操 亚洲肉感熟女色图 a片A毛片管看视频 8vaa褋芯屑 333kk 川岛和津实视频 在线母子乱伦对白 妹妹肥逼五月 亚洲美女自拍 老婆在我面前小说 韩国空姐堪比情趣内衣 干小姐综合 淫妻色五月 添骚穴 WM62COM 23456影视播放器 成人午夜剧场 尼姑福利网 AV区亚洲AV欧美AV512qucomwwwc5508com 经典欧美骚妇 震动棒露出 日韩丝袜美臀巨乳在线 av无限吧看 就去干少妇 色艺无间正面是哪集 校园春色我和老师做爱 漫画夜色 天海丽白色吊带 黄色淫荡性虐小说 午夜高清播放器 文20岁女性荫道口图片 热国产热无码热有码 2015小明发布看看算你色 百度云播影视 美女肏屄屄乱轮小说 家族舔阴AV影片 邪恶在线av有码 父女之交 关于处女破处的三级片 极品护士91在线 欧美虐待女人视频的网站 享受老太太的丝袜 aaazhibuo 8dfvodcom成人 真实自拍足交 群交男女猛插逼 妓女爱爱动态 lin35com是什么网站 abp159 亚洲色图偷拍自拍乱伦熟女抠逼自慰 朝国三级篇 淫三国幻想 免费的av小电影网站 日本阿v视频免费按摩师 av750c0m 黄色片操一下 巨乳少女车震在线观看 操逼 免费 囗述情感一乱伦岳母和女婿 WWW_FAMITSU_COM 偷拍中国少妇在公车被操视频 花也真衣论理电影 大鸡鸡插p洞 新片欧美十八岁美少 进击的巨人神thunderftp 西方美女15p 深圳哪里易找到老女人玩视频 在线成人有声小说 365rrr 女尿图片 我和淫荡的小姨做爱 � 做爱技术体照 淫妇性爱 大学生私拍b 第四射狠狠射小说 色中色成人av社区 和小姨子乱伦肛交 wwwppp62com 俄罗斯巨乳人体艺术 骚逼阿娇 汤芳人体图片大胆 大胆人体艺术bb私处 性感大胸骚货 哪个网站幼女的片多 日本美女本子把 色 五月天 婷婷 快播 美女 美穴艺术 色百合电影导航 大鸡巴用力 孙悟空操美少女战士 狠狠撸美女手掰穴图片 古代女子与兽类交 沙耶香套图 激情成人网区 暴风影音av播放 动漫女孩怎么插第3个 mmmpp44 黑木麻衣无码ed2k 淫荡学姐少妇 乱伦操少女屄 高中性爱故事 骚妹妹爱爱图网 韩国模特剪长发 大鸡巴把我逼日了 中国张柏芝做爱片中国张柏芝做爱片中国张柏芝做爱片中国张柏芝做爱片中国张柏芝做爱片 大胆女人下体艺术图片 789sss 影音先锋在线国内情侣野外性事自拍普通话对白 群撸图库 闪现君打阿乐 ady 小说 插入表妹嫩穴小说 推荐成人资源 网络播放器 成人台 149大胆人体艺术 大屌图片 骚美女成人av 春暖花开春色性吧 女亭婷五月 我上了同桌的姐姐 恋夜秀场主播自慰视频 yzppp 屄茎 操屄女图 美女鲍鱼大特写 淫乱的日本人妻山口玲子 偷拍射精图 性感美女人体艺木图片 种马小说完本 免费电影院 骑士福利导航导航网站 骚老婆足交 国产性爱一级电影 欧美免费成人花花性都 欧美大肥妞性爱视频 家庭乱伦网站快播 偷拍自拍国产毛片 金发美女也用大吊来开包 缔D杏那 yentiyishu人体艺术ytys WWWUUKKMCOM 女人露奶 � 苍井空露逼 老荡妇高跟丝袜足交 偷偷和女友的朋友做爱迅雷 做爱七十二尺 朱丹人体合成 麻腾由纪妃 帅哥撸播种子图 鸡巴插逼动态图片 羙国十次啦中文 WWW137AVCOM 神斗片欧美版华语 有气质女人人休艺术 由美老师放屁电影 欧美女人肉肏图片 白虎种子快播 国产自拍90后女孩 美女在床上疯狂嫩b 饭岛爱最后之作 幼幼强奸摸奶 色97成人动漫 两性性爱打鸡巴插逼 新视觉影院4080青苹果影院 嗯好爽插死我了 阴口艺术照 李宗瑞电影qvod38 爆操舅母 亚洲色图七七影院 被大鸡巴操菊花 怡红院肿么了 成人极品影院删除 欧美性爱大图色图强奸乱 欧美女子与狗随便性交 苍井空的bt种子无码 熟女乱伦长篇小说 大色虫 兽交幼女影音先锋播放 44aad be0ca93900121f9b 先锋天耗ばさ无码 欧毛毛女三级黄色片图 干女人黑木耳照 日本美女少妇嫩逼人体艺术 sesechangchang 色屄屄网 久久撸app下载 色图色噜 美女鸡巴大奶 好吊日在线视频在线观看 透明丝袜脚偷拍自拍 中山怡红院菜单 wcwwwcom下载 骑嫂子 亚洲大色妣 成人故事365ahnet 丝袜家庭教mp4 幼交肛交 妹妹撸撸大妈 日本毛爽 caoprom超碰在email 关于中国古代偷窥的黄片 第一会所老熟女下载 wwwhuangsecome 狼人干综合新地址HD播放 变态儿子强奸乱伦图 强奸电影名字 2wwwer37com 日本毛片基地一亚洲AVmzddcxcn 暗黑圣经仙桃影院 37tpcocn 持月真由xfplay 好吊日在线视频三级网 我爱背入李丽珍 电影师傅床戏在线观看 96插妹妹sexsex88com 豪放家庭在线播放 桃花宝典极夜著豆瓜网 安卓系统播放神器 美美网丝袜诱惑 人人干全免费视频xulawyercn av无插件一本道 全国色五月 操逼电影小说网 good在线wwwyuyuelvcom www18avmmd 撸波波影视无插件 伊人幼女成人电影 会看射的图片 小明插看看 全裸美女扒开粉嫩b 国人自拍性交网站 萝莉白丝足交本子 七草ちとせ巨乳视频 摇摇晃晃的成人电影 兰桂坊成社人区小说www68kqcom 舔阴论坛 久撸客一撸客色国内外成人激情在线 明星门 欧美大胆嫩肉穴爽大片 www牛逼插 性吧星云 少妇性奴的屁眼 人体艺术大胆mscbaidu1imgcn 最新久久色色成人版 l女同在线 小泽玛利亚高潮图片搜索 女性裸b图 肛交bt种子 最热门有声小说 人间添春色 春色猜谜字 樱井莉亚钢管舞视频 小泽玛利亚直美6p 能用的h网 还能看的h网 bl动漫h网 开心五月激 东京热401 男色女色第四色酒色网 怎么下载黄色小说 黄色小说小栽 和谐图城 乐乐影院 色哥导航 特色导航 依依社区 爱窝窝在线 色狼谷成人 91porn 包要你射电影 色色3A丝袜 丝袜妹妹淫网 爱色导航(荐) 好男人激情影院 坏哥哥 第七色 色久久 人格分裂 急先锋 撸撸射中文网 第一会所综合社区 91影院老师机 东方成人激情 怼莪影院吹潮 老鸭窝伊人无码不卡无码一本道 av女柳晶电影 91天生爱风流作品 深爱激情小说私房婷婷网 擼奶av 567pao 里番3d一家人野外 上原在线电影 水岛津实透明丝袜 1314酒色 网旧网俺也去 0855影院 在线无码私人影院 搜索 国产自拍 神马dy888午夜伦理达达兔 农民工黄晓婷 日韩裸体黑丝御姐 屈臣氏的燕窝面膜怎么样つぼみ晶エリーの早漏チ○ポ强化合宿 老熟女人性视频 影音先锋 三上悠亚ol 妹妹影院福利片 hhhhhhhhsxo 午夜天堂热的国产 强奸剧场 全裸香蕉视频无码 亚欧伦理视频 秋霞为什么给封了 日本在线视频空天使 日韩成人aⅴ在线 日本日屌日屄导航视频 在线福利视频 日本推油无码av magnet 在线免费视频 樱井梨吮东 日本一本道在线无码DVD 日本性感诱惑美女做爱阴道流水视频 日本一级av 汤姆avtom在线视频 台湾佬中文娱乐线20 阿v播播下载 橙色影院 奴隶少女护士cg视频 汤姆在线影院无码 偷拍宾馆 业面紧急生级访问 色和尚有线 厕所偷拍一族 av女l 公交色狼优酷视频 裸体视频AV 人与兽肉肉网 董美香ol 花井美纱链接 magnet 西瓜影音 亚洲 自拍 日韩女优欧美激情偷拍自拍 亚洲成年人免费视频 荷兰免费成人电影 深喉呕吐XXⅩX 操石榴在线视频 天天色成人免费视频 314hu四虎 涩久免费视频在线观看 成人电影迅雷下载 能看见整个奶子的香蕉影院 水菜丽百度影音 gwaz079百度云 噜死你们资源站 主播走光视频合集迅雷下载 thumbzilla jappen 精品Av 古川伊织star598在线 假面女皇vip在线视频播放 国产自拍迷情校园 啪啪啪公寓漫画 日本阿AV 黄色手机电影 欧美在线Av影院 华裔电击女神91在线 亚洲欧美专区 1日本1000部免费视频 开放90后 波多野结衣 东方 影院av 页面升级紧急访问每天正常更新 4438Xchengeren 老炮色 a k福利电影 色欲影视色天天视频 高老庄aV 259LUXU-683 magnet 手机在线电影 国产区 欧美激情人人操网 国产 偷拍 直播 日韩 国内外激情在线视频网给 站长统计一本道人妻 光棍影院被封 紫竹铃取汁 ftp 狂插空姐嫩 xfplay 丈夫面前 穿靴子伪街 XXOO视频在线免费 大香蕉道久在线播放 电棒漏电嗨过头 充气娃能看下毛和洞吗 夫妻牲交 福利云点墦 yukun瑟妃 疯狂交换女友 国产自拍26页 腐女资源 百度云 日本DVD高清无码视频 偷拍,自拍AV伦理电影 A片小视频福利站。 大奶肥婆自拍偷拍图片 交配伊甸园 超碰在线视频自拍偷拍国产 小热巴91大神 rctd 045 类似于A片 超美大奶大学生美女直播被男友操 男友问 你的衣服怎么脱掉的 亚洲女与黑人群交视频一 在线黄涩 木内美保步兵番号 鸡巴插入欧美美女的b舒服 激情在线国产自拍日韩欧美 国语福利小视频在线观看 作爱小视颍 潮喷合集丝袜无码mp4 做爱的无码高清视频 牛牛精品 伊aⅤ在线观看 savk12 哥哥搞在线播放 在线电一本道影 一级谍片 250pp亚洲情艺中心,88 欧美一本道九色在线一 wwwseavbacom色av吧 cos美女在线 欧美17,18ⅹⅹⅹ视频 自拍嫩逼 小电影在线观看网站 筱田优 贼 水电工 5358x视频 日本69式视频有码 b雪福利导航 韩国女主播19tvclub在线 操逼清晰视频 丝袜美女国产视频网址导航 水菜丽颜射房间 台湾妹中文娱乐网 风吟岛视频 口交 伦理 日本熟妇色五十路免费视频 A级片互舔 川村真矢Av在线观看 亚洲日韩av 色和尚国产自拍 sea8 mp4 aV天堂2018手机在线 免费版国产偷拍a在线播放 狠狠 婷婷 丁香 小视频福利在线观看平台 思妍白衣小仙女被邻居强上 萝莉自拍有水 4484新视觉 永久发布页 977成人影视在线观看 小清新影院在线观 小鸟酱后丝后入百度云 旋风魅影四级 香蕉影院小黄片免费看 性爱直播磁力链接 小骚逼第一色影院 性交流的视频 小雪小视频bd 小视频TV禁看视频 迷奸AV在线看 nba直播 任你在干线 汤姆影院在线视频国产 624u在线播放 成人 一级a做爰片就在线看狐狸视频 小香蕉AV视频 www182、com 腿模简小育 学生做爱视频 秘密搜查官 快播 成人福利网午夜 一级黄色夫妻录像片 直接看的gav久久播放器 国产自拍400首页 sm老爹影院 谁知道隔壁老王网址在线 综合网 123西瓜影音 米奇丁香 人人澡人人漠大学生 色久悠 夜色视频你今天寂寞了吗? 菲菲影视城美国 被抄的影院 变态另类 欧美 成人 国产偷拍自拍在线小说 不用下载安装就能看的吃男人鸡巴视频 插屄视频 大贯杏里播放 wwwhhh50 233若菜奈央 伦理片天海翼秘密搜查官 大香蕉在线万色屋视频 那种漫画小说你懂的 祥仔电影合集一区 那里可以看澳门皇冠酒店a片 色自啪 亚洲aV电影天堂 谷露影院ar toupaizaixian sexbj。com 毕业生 zaixian mianfei 朝桐光视频 成人短视频在线直接观看 陈美霖 沈阳音乐学院 导航女 www26yjjcom 1大尺度视频 开平虐女视频 菅野雪松协和影视在线视频 华人play在线视频bbb 鸡吧操屄视频 多啪啪免费视频 悠草影院 金兰策划网 (969) 橘佑金短视频 国内一极刺激自拍片 日本制服番号大全magnet 成人动漫母系 电脑怎么清理内存 黄色福利1000 dy88午夜 偷拍中学生洗澡磁力链接 花椒相机福利美女视频 站长推荐磁力下载 mp4 三洞轮流插视频 玉兔miki热舞视频 夜生活小视频 爆乳人妖小视频 国内网红主播自拍福利迅雷下载 不用app的裸裸体美女操逼视频 变态SM影片在线观看 草溜影院元气吧 - 百度 - 百度 波推全套视频 国产双飞集合ftp 日本在线AV网 笔国毛片 神马影院女主播是我的邻居 影音资源 激情乱伦电影 799pao 亚洲第一色第一影院 av视频大香蕉 老梁故事汇希斯莱杰 水中人体磁力链接 下载 大香蕉黄片免费看 济南谭崔 避开屏蔽的岛a片 草破福利 要看大鸡巴操小骚逼的人的视频 黑丝少妇影音先锋 欧美巨乳熟女磁力链接 美国黄网站色大全 伦蕉在线久播 极品女厕沟 激情五月bd韩国电影 混血美女自摸和男友激情啪啪自拍诱人呻吟福利视频 人人摸人人妻做人人看 44kknn 娸娸原网 伊人欧美 恋夜影院视频列表安卓青青 57k影院 如果电话亭 avi 插爆骚女精品自拍 青青草在线免费视频1769TV 令人惹火的邻家美眉 影音先锋 真人妹子被捅动态图 男人女人做完爱视频15 表姐合租两人共处一室晚上她竟爬上了我的床 性爱教学视频 北条麻妃bd在线播放版 国产老师和师生 magnet wwwcctv1024 女神自慰 ftp 女同性恋做激情视频 欧美大胆露阴视频 欧美无码影视 好女色在线观看 后入肥臀18p 百度影视屏福利 厕所超碰视频 强奸mp magnet 欧美妹aⅴ免费线上看 2016年妞干网视频 5手机在线福利 超在线最视频 800av:cOm magnet 欧美性爱免播放器在线播放 91大款肥汤的性感美乳90后邻家美眉趴着窗台后入啪啪 秋霞日本毛片网站 cheng ren 在线视频 上原亚衣肛门无码解禁影音先锋 美脚家庭教师在线播放 尤酷伦理片 熟女性生活视频在线观看 欧美av在线播放喷潮 194avav 凤凰AV成人 - 百度 kbb9999 AV片AV在线AV无码 爱爱视频高清免费观看 黄色男女操b视频 观看 18AV清纯视频在线播放平台 成人性爱视频久久操 女性真人生殖系统双性人视频 下身插入b射精视频 明星潜规测视频 mp4 免賛a片直播绪 国内 自己 偷拍 在线 国内真实偷拍 手机在线 国产主播户外勾在线 三桥杏奈高清无码迅雷下载 2五福电影院凸凹频频 男主拿鱼打女主,高宝宝 色哥午夜影院 川村まや痴汉 草溜影院费全过程免费 淫小弟影院在线视频 laohantuiche 啪啪啪喷潮XXOO视频 青娱乐成人国产 蓝沢润 一本道 亚洲青涩中文欧美 神马影院线理论 米娅卡莉法的av 在线福利65535 欧美粉色在线 欧美性受群交视频1在线播放 极品喷奶熟妇在线播放 变态另类无码福利影院92 天津小姐被偷拍 磁力下载 台湾三级电髟全部 丝袜美腿偷拍自拍 偷拍女生性行为图 妻子的乱伦 白虎少妇 肏婶骚屄 外国大妈会阴照片 美少女操屄图片 妹妹自慰11p 操老熟女的b 361美女人体 360电影院樱桃 爱色妹妹亚洲色图 性交卖淫姿势高清图片一级 欧美一黑对二白 大色网无毛一线天 射小妹网站 寂寞穴 西西人体模特苍井空 操的大白逼吧 骚穴让我操 拉好友干女朋友3p